OFFPRINTED FROM Moral Particularism

L. Blum

Abstract:

What problem does this paper attempt to address?

Robotic Assisted Percutaneous Coronary Intervention: Initial Australian Experience

James Leung,John French,James Xu,Hashim Kachwalla,Krishna Kaddapu,Tamer Badie,Christian Mussap,Rohan Rajaratnam,Dominic Leung,Sidney Lo,Craig Juergens

DOI: https://doi.org/10.1016/j.hlc.2024.01.019

2024-02-01

Abstract:BACKGROUND & AIM: <AbstractText Label="BACKGROUND & AIM" NlmCategory="OBJECTIVE">Robotic-assisted percutaneous coronary intervention (R-PCI) has been increasingly performed overseas. Initial observations have demonstrated its clinical efficacy and safety with additional potential benefits of more accurate lesion assessment and stent deployment, with reduced radiation exposure to operators and patients. However, data from randomised controlled trials or clinical experience from Australia are lacking.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">This was a single-centre experience of all patients undergoing R-PCI as part of the run-in phase for an upcoming randomised clinical trial (ACTRN12623000480684). All R-PCI procedures were performed using the CorPath GRX robot (Corindus Vascular Robotics, Waltham, Massachusetts, USA). Key inclusion criteria included patients with obstructive coronary disease requiring percutaneous coronary intervention. Major exclusion criteria included ST-elevation myocardial infarction, cardiogenic shock or lesions deemed unsuitable for R-PCI by the operator. Clinical success was defined as residual stenosis <30% without in-hospital major adverse cardiovascular events (MACE). Technical success was defined as the completion of the R-PCI procedure without unplanned manual conversion. Procedural characteristics were compared between early (cases 1-3) and later (cases 4-21) cases.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-one (21) patients with a total of 24 lesions were analysed. The mean age of patients was 66.5 years, and 66% of cases were male. Radial access was used in 18 cases (86%). Most lesions were American Heart Association/American College of Cardiology class B2/C (66%). Clinical success was achieved in 100% with manual conversion required in four cases (19%). No procedural complications or in-hospital MACE occurred. Compared to the early cases, later cases had a statistically significantly shorter fluoroscopy time (44.0mins vs 25.2mins, p<0.007), dose area product (967.3 dGy.cm<sup>2</sup> vs 361.0dGy.cm<sup>2</sup>, p=0.01) and air kerma (2484.3mGy vs 797.4mGy, p=0.009) with no difference in contrast usage (136.7mL vs 131.4mL, p=0.88).</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We present the first clinical experience of R-PCI in Australia using the Corindus CorPath GRX robot. We achieved clinical success in all patients and technical success in the majority of cases with no procedural complications or in-hospital MACE. With increasing operator and staff experience, cases required shorter fluoroscopy time and less radiation exposure but similar contrast usage.</AbstractText>

cardiac & cardiovascular systems
Second-generation robotic angioplasty system use for the treatment of ST-elevation myocardial infarction: a first-in-man proof of concept case report

Felix J Hofmann,Oliver Dörr,Florian Blachutzik,Albrecht Elsässer,Helge Möllmann,Alessa-Janine Köhne,Holger M Nef

DOI: https://doi.org/10.1093/ehjcr/ytad089

2023-03-01

European Heart Journal - Case Reports

Abstract:Abstract Background Robotically assisted remote-controlled PCI (rPCI) was introduced in the past decade as one of the latest enhancements in this rapidly evolving field. The use of a second-generation rPCI system in ST-elevation myocardial infarction (STEMI) is an effort to couple immediate revascularization with the accuracy of newer robotic assistance and software support. Case summary Here we report on the safety and efficacy of rPCI applied to a 74-year-old female STEMI patient with persistent acute chest pain as well as regional wall motion abnormalities in the echocardiogram. The first medical contact-to-device time was 76 min, and door-to-balloon time was 33 min. The impatient course was uneventful, so the patient was discharged from hospital after 5 days. To the best of our knowledge, this is the first report of the successful application of second-generation rPCI in STEMI. Discussion In the case presented, rPCI was feasible and safe even in acute coronary syndrome based on a single-centre experience. rPCI is a revolutionary new technique that may be applied to various types of clinical presentations.
CorPath GRX robotic interventional system for percutaneous coronary intervention: a case report and literature review

吴轶喆,葛均波,朱鸣辉,陈章炜,李晨光,常书福,齐鹏,陆浩,戴宇翔

DOI: https://doi.org/10.3760/cma.j.cn116031.2021.1000093

2021-01-01

Abstract:Objective:To evaluate the current status of robot-assisted percutaneous coronary intervention (PCI) based on the latest generation of the CorPath GRX robotic interventional system.Clinical Feature:A 60-year-old male was admitted due to "repeated chest tightness and chest pain for half a year". Computed tomography angiography suggested "severe stenosis in the middle segment of the left anterior descending branch and the proximal segment of the first diagonal branch". The patient was clinically diagnosed with coronary atherosclerotic heart disease, unstable angina pectoris, hypertension, type 2 diabetes, chronic renal insufficiency, and gout. In March 13, 2021, this patient became the first case wherein PCI was performed by the latest generation of the CorPath GRX robotic system in Hainan Bo' ao Super Hospital. After 3 months of telephone follow-up,the patient's chest pain symptoms were completely improved, and no adverse events occurred.Data Review:We searched the PubMed, Web of Science, CNKI, and Wanfang databases. The search terms included "robotic", "percutaneous coronary intervention", and "robotic assisted". The retrieval time was July 31, 2021. A total of 203 articles that met the criteria were identified. After further screening of the titles and abstracts, 74 articles of clinical research reports and clinical research reports on robot-assisted PCI were obtained. Since the first robot-assisted PCI was performed in 2006, more than 10 000 operations have been performed worldwide, including for chronic occlusive diseases and other complex lesions. Robot-assisted PCI had a good performance in terms of surgical results and shortening the operation time, and there have been no reports of serious complications.Conclusion:The CorPath GRX robotic interventional system provides a more accurate and standard mode for coronary interventional therapy.
A Novel Robotic Control System Mimics Doctor’s Operation to Assist Percutaneous Coronary Intervention

Boda Zhou,Qizhong Li,Yajun Xue,Lihao Huang,Jie Zhou,Ou Zhang,Ping Zhang,Gangtie Zheng

DOI: https://doi.org/10.15212/cvia.2022.0003

2022-01-01

Cardiovascular Innovations and Applications

Abstract:Objectives: The use of current robotic systems to assist in percutaneous coronary intervention (PCI) fundamentally differs from performing conventional PCI. To overcome this problem, we developed a novel master-slave robotic control system to assist in PCI, and evaluated its safety and feasibility in the delivery and manipulation of coronary guidewires in vitro and in vivo . Methods: The novel robotic assist PCI system is composed of three parts: 1) a master actuator, which imitates the traditional torque used by surgeons in conventional PCI, 2) a slave actuator, including a guidewire delivery system and force monitoring equipment, and 3) a local area network based communication system. Results: The experiment was performed in six pigs. Both robotic and manual control completed the operation with no device- or procedure-associated complications. An experienced interventional cardiologist who was a first-time user of the novel robotic PCI system was able to advance the guidewire into a distal branch of a coronary artery within a similar time to that required with the manual procedure. Conclusion: This early in vivo experiment with the novel robotic assisted PCI control system demonstrated that its feasibility, safety, and procedural effectiveness are comparable to those of manual operation. The novel robotic-assisted PCI control system required significantly less time to learn than other currently available systems.
Robotics in percutaneous cardiovascular interventions

Ali Pourdjabbar,Lawrence Ang,Omid Behnamfar,Mitul P. Patel,Ryan R. Reeves,Paul T Campbell,Ryan D Madder,Ehtisham Mahmud

DOI: https://doi.org/10.1080/14779072.2017.1377071

2017-09-15

Expert Review of Cardiovascular Therapy

Abstract:INTRODUCTION: The fundamental technique of performing percutaneous cardiovascular (CV) interventions has remained unchanged and requires operators to wear heavy lead aprons to minimize exposure to ionizing radiation. Robotic technology is now being utilized in interventional cardiology partially as a direct result of the increasing appreciation of the long-term occupational hazards of the field. This review was undertaken to report the clinical outcomes of percutaneous robotic coronary and peripheral vascular interventions. Areas covered: A systematic literature review of percutaneous robotic CV interventions was undertaken. The safety and feasibility of percutaneous robotically-assisted CV interventions has been validated in simple to complex coronary disease, and iliofemoral disease. Studies have shown that robotically-assisted PCI significantly reduces operator exposure to harmful ionizing radiation without compromising procedural success or clinical efficacy. In addition to the operator benefits, robotically-assisted intervention has the potential for patient advantages by allowing more accurate lesion length measurement, precise stent placement and lower patient radiation exposure. However, further investigation is required to fully elucidate these potential benefits. Expert commentary: Incremental improvement in robotic technology and telecommunications would enable treatment of an even broader patient population, and potentially provide remote robotic PCI.
Multiple endokrine Neoplasie assoziiert mit multiplen Lipomen

Marion A. Hofmann,T. Schilling,P. Heilmann,O. Haisken,C. Wüster,M. L. Brandi,R. Ziegler,P. Nawroth

DOI: https://doi.org/10.1007/BF03042664

1998-09-01

Medizinische Klinik

Abstract:
Local anaesthetic effects on trophoblast membrane fluidity.

R. Staffolani,N. Cester,R. Magnanelli,M. Familiari,P. Pigini,C. Tonnini,G. Lenaz,L. Mazzanti

1993-03-01

Abstract:Previous studies showed that anaesthesia with the barbiturate Thiopental induces an increase in membrane fluidity and a decrease in acetylcholinesterase activity in syncytiotrophoblast plasma membranes (SPM) obtained from placentas after Cesarean section. The aim of the present work was to compare the effect of a local anaesthetic (bupivacaine hydrochloride, trade name Marcaine) on SPM in vivo and to establish whether the anaesthetic is still present in the membrane after tissue preparation. The acetylcholinesterase activity was lower in Marcaine-anaesthetized SPM (27 +/- 3 against 39 +/- 6 in the control). The Marcaine action on the SPM can be ascribed to a competitive inhibition, similar to that reported for Thiopental. Fluorescence studies of the order parameter P showed it to be higher in SPM obtained from control (0.253 +/- 0.012) than in SPM obtained from Marcaine-exposed membranes (0.240 +/- 0.015). The local anaesthetic is still present in the SPM after their preparation (20.1 ng per mg membrane protein). It appears that the local anaesthetic exhibits an effect similar to that of the general anaesthetic, apparently due to binding to the membrane.
Latest Developments in Robotic Percutaneous Coronary Interventions

Arif A Khokhar,Andrea Marrone,Konstantinos Bermpeis,Eric Wyffels,Maria Tamargo,Francisco Fernandez-Avilez,Rossella Ruggiero,Adriana Złahoda-Huzior,Francesco Giannini,Aleksander Zelias,Ryan Madder,Dariusz Dudek,Rafael Beyar

DOI: https://doi.org/10.15420/icr.2023.03

2023-12-06

Abstract:Since the first robotic-assisted percutaneous coronary intervention procedure (R-PCI) was performed in 2004, there has been a steady evolution in robotic technology, combined with a growth in the number of robotic installations worldwide and operator experience. This review summarises the latest developments in R-PCI with a focus on developments in robotic technology, procedural complexity, tele-stenting and training methods, which have all contributed to the global expansion in R-PCI.
Abstract 11630: Comparing Outcomes Between Robotic Assisted versus Manual Percutaneous Coronary Intervention - A Meta-Analysis of 2,203 Patients

Rahul Gupta,aaqib malik,Surya K Aedma,Wilbert S Aronow,Apurva Vyas,Sanjay Mehta,William G Combs,Nainesh Patel

DOI: https://doi.org/10.1161/circ.144.suppl_1.11630

IF: 37.8

2021-11-16

Circulation

Abstract:Introduction: Robotics in percutaneous coronary intervention (R-PCI) has been one such area of advancement where potential benefits may include reduction in radiation exposure, improved outcomes and reduced rate of adverse events. Robotic assistance may offer many potential benefits to both the operator and the patient. Limited data exist about the benefits of R-PCI vs. conventional manual PCI (M-PCI). Hypothesis: The aim for our meta-analysis is to evaluate the procedural measures and clinical outcomes between R-PCI and M-PCI. Methods: A comprehensive literature search was performed in PubMed, Embase, and Cochrane to identify relevant clinical studies. Summary effects were calculated using a DerSimonian and Laird random effects model as odds ratio with 95% confidence intervals for all the clinical endpoints. All studies adhering to the inclusion criteria of direct comparisons between R-PCI and M-PCI were evaluated. Results: Seven studies with a total of 2,230 patients were identified. There was significant decrease in the chest-level operator radiation exposure (OR= -442.32; 95% CI = -675.88 to -208.76), fluoroscopy time (OR = -1.46; 95% CI -2.92 to 0.00) and amount of contrast used (OR= -18.28; 95% CI -24.16 to -12.41) in the robotic group as compared to the manual group. PCI time (OR = 2.41; 95% CI -3.95 to 8.76) and procedural success rate (OR 1.26; CI 0.19-8.22) was not statistically different between the two groups. In terms of clinical outcomes, there was no difference between R-PCI and M-PCI in terms of major adverse cardiac events (OR 0.90; CI 0.45-1.79), all-cause mortality (OR 0.95; CI 0.21-4.30), and myocardial infarction (OR 0.88; CI 0.41-1.89). Conclusions: Robotic PCI is associated with reduced operator radiation exposure, fluoroscopy time and amount of contrast used. While there is a significant reduction in the procedural characteristics with robotic PCI, the clinical outcomes are not different compared to manual PCI. Use of robotics in PCI appears to be safe and potentially favorable to the patients, in addition to its benefits of improved ergonomics. More randomized studies looking at the use of R-PCI, especially in complex lesions, are needed before consideration for widespread implementation.

cardiac & cardiovascular systems,peripheral vascular disease
Protected high risk percutaneous coronary intervention-Impella 5.0 as a single-access technique: a case report

Marta Medina,Philip Wenzel,Bilel Fathallah,Tobias Ruf,Mehmet Oezkur

DOI: https://doi.org/10.1093/ehjcr/ytae060

2024-01-30

Abstract:Background: Patients requiring coronary intervention after acute myocardial infarction, with decompensated heart failure and multiple co-morbidities, present a challenging clinical scenario. Addressing such high-risk cases has been a marked increase in the simultaneous support using microaxial flow pump devices, providing a crucial haemodynamic support during procedures. Case summary: We report the case of a 58-year-old man, with a non-ST-segment elevation myocardial infarction in the context of a peripheral vascular surgery. Echocardiography revealed severely reduced left ventricular function and cardiac magnetic resonance imaging demonstrated transmural scars in all but left anterior descending artery area. The patient was of extreme high surgical risk due to the multiple co-morbidities, acute decompensation heart failure, and peripheral artery disease, and, therefore, the heart team preferred protected percutaneous coronary intervention (PCI) over coronary artery bypass graft for revascularization. The peripheral artery disease included severely calcified ascending aorta, occlusions of both femoral arteries, the left subclavian artery, and the right radial artery. Taken together, the heart team agreed on a hybrid approach with surgical implantation of Impella 5.0 via the left subclavian artery, by a single-access technique. Following the intervention procedure, haemostasis of the vascular prosthesis was achieved by an angio-seal technique without complications. The patient recovered satisfactorily, with improved left ventricular function, and discharged 10 days post-procedure. Discussion: The single-access high-risk PCI technique offers a standardized approach for microaxial flow pump devices such as Impella 5.0 and PCI. The subclavian artery as a single-access route for high-risk PCI has demonstrated safety and efficacy.
Robotic assisted carotid artery stenting for the treatment of symptomatic carotid disease: technical feasibility and preliminary results

Raul G Nogueira,Rajesh Sachdeva,Alhamza R Al-Bayati,Mahmoud H Mohammaden,Michael R Frankel,Diogo C Haussen

DOI: https://doi.org/10.1136/neurintsurg-2019-015754

Abstract:Background and purpose: Robotic-assisted endovascular interventions have been increasingly performed in the coronary and peripheral vascular beds. We aim to describe the feasibility and initial safety of a robotic-assisted platform for treating carotid artery disease. Methods: Single-center technical report of the first four consecutive cases of carotid artery stenting for the treatment of severe symptomatic carotid stenosis utilizing the CorPath GRX Robotic System (Corindus Inc, Waltham, MA). Results: Four patients (one in early 60s and three in early 70s; NASCET degree of stenosis: 88%, 77%, 83% and 82%) with ipsilateral strokes on presentation were treated. All steps of the procedure (including delivery/removal of micro-guidewire, emboli-protection system and angioplasty balloon) could be successfully performed robotically with the exception of navigation/deployment of the stents due to incompatibility with the current robotic platform. Technical success was achieved in all patients resulting in resolution of the stenosis without any complications. Conclusions: Robotic-assisted carotid artery stenting is technically feasible. Future studies are warranted to properly establish safety and benefits.
Mid-term Clinical Outcomes of Robotic-Assisted Reverse Hybrid Coronary Revascularization. A Single Center Experience.

Aleksander Dokollari,Marco Gemelli,Serge Sicouri,William A. Gray,Timothy A. Shapiro,Frank McGeehin,Marwan Badri,Paul Coady,Eric Gnall,Mara Caroline,Amid A. Khan,Massimo Bonacchi,Francesco Cabrucci,Beatrice Bacchi,Bruno Chiarello,Ashish Shah,Aaron Spooner,Nitin Ghorpade,Ali Fatehi Hassanabad,Stephanie Kjelstrom,Georgia Montone,Mary Ann Wertan,Basel Ramlawi,Francis P. Sutter

DOI: https://doi.org/10.1016/j.amjcard.2023.12.054

IF: 3.133

2024-01-07

The American Journal of Cardiology

Abstract:BACKGROUND Outcomes of robotic-assisted reverse hybrid coronary revascularization (HCR) remain hindered. We aim to analyze mid-term clinical outcomes of robotic-assisted reverse HCR. METHODS All consecutive 285 patients that underwent reverse robotic-assisted HCR between 09/2005-07/2021 are included. Reverse HCR consists of percutaneous coronary intervention (PCI) with stent implantation in non-left anterior descending (LAD) coronary artery vessels performed within 30-days prior to robotic-assisted left internal thoracic artery (LITA) harvesting and LITA to LAD manual anastomosis through a 4-cm left minithoracotomy. Dual antiplatelet therapy was not interrupted on any patient. RESULTS Preoperatively, mean age was 70.2 (± 11.2) years old. Prior to surgery, a total of 168 patients received 1 stent, 112 patients 2 stents, and 5 patients 3 stents. Intraoperatively, mean OR time was 5.9 (± 1) hours, no case was converted to full sternotomy, while 9 (3.1%) patients received intraoperative blood products transfusions. Postoperatively, a low incidence of stroke 1 (0.3%), reoperation for bleeding 7 (2.4%), blood product transfusions 48 (16.8%), and hospital stay (4.8 days) was observed. At 30-day follow-up, 1 (0.3%) patient underwent PCI with stent on a surgical LITA-LAD anastomosis due to graft failure. Mean follow-up was 4.2-years. Reported mid-term outcomes included all-cause death in 31 patients (10.9%), MACCE in 102/285 (35.9%), nonfatal stroke in 2/285 (0.7%), MI in 17/285 (5.9%), and repeat intervention in 50/285 (17.5%) patients. CONCLUSION This single center study reports effective and safe clinical outcomes at mid-term follow-up of reverse HCR procedures for treatment of multivessel coronary artery disease.

cardiac & cardiovascular systems
A Systematic Review of R-PCI

Max Wagener,Yoshinobu Onuma,Ruth Sharif,Eileen Coen,William Wijns,Faisal Sharif

DOI: https://doi.org/10.3390/jcm13185537

IF: 3.9

2024-09-20

Journal of Clinical Medicine

Abstract:Background: Ischaemic heart disease is one of the major drivers of cardiovascular death in Europe. Since the first percutaneous coronary intervention (PCI) in 1977, developments and innovations in cardiology have made PCI the treatment of choice for stenotic coronary artery disease. To address the occupational hazards related to chronic exposure to radiation and wear and tear from heavy lead-based radioprotective aprons, the concept of robotically assisted PCI (R-PCI) was introduced in 2005. Aim: To explore the features and limitations of R-PCI, we first discuss the concept and evolution of R-PCI platforms and then systematically review the available clinical data. Methods: A systematic review has been performed across the Pubmed, Embase and Cochrane databases in order to assess the efficacy and safety of R-PCI. Secondary endpoints, such as operator and patient exposure to radiation, contrast volume used and procedural time, were assessed when available. Results: In selected patients, R-PCI provides high technical and clinical success rates, ranging from 81 to 98.8% and from 93.3 to 100%, respectively. In-hospital and 1-year MACE rates ranged from 0 to 10.4% and 4.8 to 10.5%, respectively. R-PCI is able to significantly reduce the operator's exposure to radiation. Further research analysing the patient's and cath lab staff's exposure to radiation is needed. Therapy escalation with R-PCI seems to be limited to complex lesions. R-PCI procedures add approximately 10 min to the procedural time. Conclusions: The efficacy and safety of R-PCI have been proven, and R-PCI is able to significantly reduce occupational hazards for the first operator. The lack of adoption in the community of interventional cardiologists may be explained by the fact that current generations of R-PCI platforms are limited by their incompatibility with advanced interventional devices and techniques needed for escalation in complex interventions.

medicine, general & internal
[Individual characteristics of the brain energy metabolism during local ischemia obtained by nuclear magnetic resonance in vivo].

N. Semenova,A. Topchian,R. S. Mirzoian,A. Konradov,M. G. Balasanian

Abstract:
Long-distance Tele-robotic-assisted Percutaneous Coronary Intervention: A Case Report of First-in-patient in China

Kai Xu,Xuebin Cao,Haiwei Liu,Shenghua Zhou,Zhaochuan Liu,Xianghe Wang,Quanmin Jing,Yaling Han

DOI: https://doi.org/10.1097/cd9.0000000000000131

2024-01-01

Cardiology Discovery

Abstract:Robotic-assisted percutaneous coronary intervention (R-PCI) is an innovative way of performing percutaneous coronary intervention (PCI) whereby the operator can manipulate coronary intraluminal guidewires and catheter devices by using remotely controlled technology. Performing tele-R-PCI from a remote location via fifth generation network communication technology has never been reported in China; however, if this were possible, the technique could be used to treat many patients with coronary artery disease who would otherwise not have the opportunity of treatment. The case of a 73-year-old male patient with coronary artery disease who underwent successful tele-R-PCI at 800 km from the operators is presented. Performing long-distance tele-R-PCI in patients with coronary artery disease is feasible with predictably successful outcomes when reliable network connectivity and local cardiac catheterization facilities are present.
Comparison of Robotic Percutaneous Coronary Intervention With Traditional Percutaneous Coronary Intervention

Tejas M. Patel,Sanjay C. Shah,Yash Y. Soni,Rajni C. Radadiya,Gaurav A. Patel,Pradyot O. Tiwari,Samir B. Pancholy

DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.119.008888

2020-05-15

Abstract:Robotic percutaneous coronary intervention (R-PCI) has been shown to benefit the operator but has not shown any significant benefit to the patient. We sought to compare a large cohort of R-PCI to traditional percutaneous coronary intervention (PCI) procedures performed at a tertiary care center in the same time frame. A total of 996 consecutive patients referred for PCI between December 2017 and March 2019 were studied, of which 310 (31.1%) patients were selected to undergo R-PCI and 686 (68.9%) patients underwent traditional PCI. The coprimary study outcome measures were air kerma, dose-area product, fluoroscopy time, volume of contrast, and total procedural time. Caliper propensity-matching technique was used (caliper, 0.05) to match each R-PCI patient to the nearest traditional PCI patient without replacement. Air kerma (mGy; median [interquartile range]; P ; 884 [537–1398] versus 1110 [699–1498]; P =0.002) and dose-area product (cGycm 2 ; 4734 [2695–7746] versus 5746 [3751–7833]; P =0.003) were significantly lower in the R-PCI group. There was no difference in fluoroscopy time (minutes; 5.51 [3.53–8.31] versus 5.48 [3.31–9.37]; P =0.936) and contrast volume (mL; 130 [103–170] versus 140 [100–180]; P =0.905). Total procedural time (minutes) was significantly higher in the R-PCI group (27 [21–40] versus 37 [27–50]; P <0.0005). R-PCI is associated with a significant decrease in radiation exposure to the patient with no increase in fluoroscopy time, as well as contrast utilization, and a minor increase in procedure duration compared with traditional PCI. Download figure Download PowerPoint
Robotic Totally Endoscopic Off-Pump Unroofing of Myocardial Bridge: Early Experience and Midterm Outcomes

Sarah Nisivaco,John Blair,Amit Patel,Hiroto Kitahara,Tess Allan,Brooke Patel,Charocka Coleman,Husam H Balkhy

DOI: https://doi.org/10.1177/15569845241266817

Abstract:Objective: Myocardial bridging (MB) occurs when a coronary artery, commonly the left anterior descending (LAD), has an intramyocardial course. In symptomatic patients who fail medical therapy, surgical unroofing can provide symptomatic relief by improving coronary blood flow. We present a series of patients undergoing robotic totally endoscopic beating-heart MB unroofing. Methods: There were 34 patients with an LAD-MB who failed medical therapy and underwent robotic totally endoscopic, off-pump unroofing between January 2017 and October 2023. Patients were evaluated by a multidisciplinary team and underwent provocative coronary angiography to confirm hemodynamic significance. We reviewed perioperative outcomes and contacted patients for midterm follow-up, including completion of a modified Seattle Angina Questionnaire (SAQ). Results: The mean age was 48 ± 8 years, and 56% were female patients. One patient had prior septal myectomy via sternotomy. All patients had significant dobutamine Pd/Pa reduction on preoperative coronary angiography. One patient had atrial fibrillation and underwent concomitant ablation with left atrial appendage ligation. The mean procedure time was 140 ± 69 min. All were completed totally endoscopically off-pump without intraoperative conversions. The mean MB length was 4.5 ± 1.4 cm, and the mean depth was 1.6 ± 0.9 cm. Of the patients, 76% were extubated in the operating room. The mean intensive care unit and hospital length of stay were 0.97 ± 0.58 and 1.73 ± 1.1 days, respectively. There were no mortalities or strokes. There was 1 postoperative take-back for bleeding. At midterm follow-up (19 ± 14 months), 28 patients completed the SAQ; 86% reported "much less angina" during activity compared with before surgery, and 93% reported taking no antianginal medication since surgery. Conclusions: In appropriate patients with hemodynamically significant LAD-MB who fail medical therapy, robotic beating-heart unroofing is possible with good outcomes. Further studies are warranted.
Twelve-month outcome of robotic assisted PCI

J Rilinger,M Jeuck,T Maulhardt,T Hartikainen,D Westermann,C Von Zur Muehlen

DOI: https://doi.org/10.1093/eurheartj/ehae666.1448

IF: 39.3

2024-10-28

European Heart Journal

Abstract:Background Robotics in interventional cardiology (R-PCI) is a technique with high potential for optimising the outcome of patients with coronary heart disease. In order to compare R-PCI with conventional, manual PCI (M-PCI), it is necessary to analyse both the index procedure during the initial hospital stay and, in particular, the long-term outcome. Methods We report twelve-month follow up data of our prospective FRiK registry, started in mid 2021. This registry focuses on success rates and safety, radiation dose of patients and personnel as well as long-term outcome (after 6 and 12 months). Moreover, R-PCI is compared with M-PCI in these categories. Results 73 patients received R-PCI. PCI success rate was 100%, with 17.8% requiring manual assistance. Rate of complications (MACE - major adverse cardiovascular events) was 0%. Compared with 152 M-PCI patients, treated by the same interventionalists, there was a higher median procedural time (diagnostic and intervention) 102.5 (82.8-123.5) min vs. 73 (51-101.5) (p<0.001) and fluoroscopy time 18.3 (14.4-26.6) min vs. 16.2 (9.8-23.4) min (p=0.037) in R-PCI patients. However, there was no significant difference between the dose-area product 4062 (2337-5990) cGycm2 vs. 3747 (2238-5904) cGycm2 (p=0.878) and contrast volume use 180 (140-250) ml vs. 180 (135-235) ml (p=0.370, figure 1). Twelve months after the intervention, all patients in both groups were alive. R-PCI and M-PCI had comparable rates of rehospitalisation (11.4% vs. 8.1%, p=0.903) and unscheduled PCI (4.3% vs. 2.7%, p=0.932, figure 2). Target vessel failure occurred in one vs. two patients in the R-PCI and M-PCI group, respectively (1.4% vs. 1.3%, p=0.932). Conclusion R-PCI showed a high success rate, low rates for need of manual assistance, and a very high safety profile without any complications. Also at 12-month follow-up, R-PCI was comparable to the M-PCI in all categories.Comparison of procedural characteristicsComparison of twelve-month outcome

cardiac & cardiovascular systems
Simultaneous therapy with pressure-controlled intermittent coronary sinus occlusion and left ventricular support during high-risk percutaneous coronary intervention: a case report

Erick D Martinez Maldonado,Guillermo Bastos Fernandez,Berenice Caneiro Queija,Erick M Avila Gil,Victor A Jimenez Diaz

DOI: https://doi.org/10.1093/ehjcr/ytae456

2024-08-29

Abstract:Background: Previous studies in patients with ST-segment elevation acute myocardial infarction treated with primary angioplasty and supported by the PiCSO® system have shown a modest yet significant absolute reduction in the infarcted myocardial area. However, the simultaneous use of PiCSO® and Impella CP® during high-risk percutaneous coronary intervention (PCI) procedures has not been reported. Case summary: A 76-year-old Caucasian man presented with severe and highly calcified left main coronary disease and severely depressed left ventricular function. As coronary bypass surgery was deemed prohibitive, successful PCI was performed with the simultaneous use of PiCSO® and Impella CP® to mitigate damage from distal microembolization and provide mechanical circulatory support to the left ventricle during the high-risk PCI procedure. Discussion: Our case exemplifies for the first time the simultaneous use of PiCSO® and Impella CP® during a high-risk PCI. This case suggests the feasibility and safety of combining both devices for mechanical haemodynamic and microcirculatory support simultaneously in specific cases during high-risk PCI, offering hope for reducing post-PCI myocardial damage in a selected population of patients.
Re: “Sliding Tarsal Advancement Flap for Upper Eyelid Reconstruction”

A. McNab,F. Irvine

DOI: https://doi.org/10.3109/01676830.2015.1049619

2015-07-13

Orbit

Abstract:We read this paper with interest but were dismayed to find that a much earlier publication of ours describing the technique was not referenced. In that paper, we described the exact same technique and results of upper eyelid marginal defect repair in 8 patients. One additional reconstructive aspect, which we described and which was not employed by Malik and Shah-Desai, is how best to handle the recessed levator muscle complex and recreate an appropriate upper eyelid crease. We describe a method of passing sutures from the recessed edge of the levator aponeurosis through the full thickness of the upper eyelid myocutaneous flap at the appropriate level to help maintain eyelid height and also to create an upper eyelid crease. It is now easier than ever to perform literature searches. It is the responsibility of both authors and reviewers to make sure that claims of precedence are appropriate.

OFFPRINTED FROM Moral Particularism

Robotic Assisted Percutaneous Coronary Intervention: Initial Australian Experience

Second-generation robotic angioplasty system use for the treatment of ST-elevation myocardial infarction: a first-in-man proof of concept case report

CorPath GRX robotic interventional system for percutaneous coronary intervention: a case report and literature review

A Novel Robotic Control System Mimics Doctor’s Operation to Assist Percutaneous Coronary Intervention

Robotics in percutaneous cardiovascular interventions

Multiple endokrine Neoplasie assoziiert mit multiplen Lipomen

Local anaesthetic effects on trophoblast membrane fluidity.

Latest Developments in Robotic Percutaneous Coronary Interventions

Abstract 11630: Comparing Outcomes Between Robotic Assisted versus Manual Percutaneous Coronary Intervention - A Meta-Analysis of 2,203 Patients

Protected high risk percutaneous coronary intervention-Impella 5.0 as a single-access technique: a case report

Robotic assisted carotid artery stenting for the treatment of symptomatic carotid disease: technical feasibility and preliminary results

Mid-term Clinical Outcomes of Robotic-Assisted Reverse Hybrid Coronary Revascularization. A Single Center Experience.

A Systematic Review of R-PCI

[Individual characteristics of the brain energy metabolism during local ischemia obtained by nuclear magnetic resonance in vivo].

Long-distance Tele-robotic-assisted Percutaneous Coronary Intervention: A Case Report of First-in-patient in China

Comparison of Robotic Percutaneous Coronary Intervention With Traditional Percutaneous Coronary Intervention

Robotic Totally Endoscopic Off-Pump Unroofing of Myocardial Bridge: Early Experience and Midterm Outcomes

Twelve-month outcome of robotic assisted PCI

Simultaneous therapy with pressure-controlled intermittent coronary sinus occlusion and left ventricular support during high-risk percutaneous coronary intervention: a case report

Re: “Sliding Tarsal Advancement Flap for Upper Eyelid Reconstruction”